ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Felmetatug vedotin’s exit could be bad news for Mersana.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
